Suppr超能文献

美国的肝脏移植

Liver transplantation in the United States.

作者信息

Qiu Jianxin, Ozawa Miyuki, Terasaki Paul I

机构信息

Terasaki Foundation Laboratory, Los Angeles, CA, USA.

出版信息

Clin Transpl. 2005:17-28.

Abstract

Based on the data reported to the OPTN/UNOS Liver Transplant Registry between 1987-2005, we found: 1. The number of deceased-donor liver transplantations increased slowly each year, with most of the increase being in adult recipients. The number of LD transplants, on the other hand, decreased sharply after 2002, following 3 years of rapid increase from 1998-2001 in both pediatric and adult recipients. 2. The number of DD liver recipients with non-cholestatic liver diseases increased very quickly during the past 18 years. Malignant disease as a cause of end-stage liver disease increased after implementation of MELD in 2002. Among LD liver recipients, non-cholestatic disease increased sharply from 1998-2001, but decreased from 2002. Malignant diseases as a cause for LD transplants decreased after 2002. 3. Among pediatric recipients, LD transplants provided better 5-year graft survival rates than transplants from deceased donors; in contrast, LD transplants in adults had poorer graft survival rates than those from deceased donors. 4. The use of marginal donors, including older donors, HCV (+) donors, donation after cardiac death donors, and diabetic donors, increased in the past 18 years. HCV(+) livers transplanted into HCV(+) cirrhosis recipients had similar graft survival when compared with HCV(-) donor livers, whereas when they were transplanted into non-HCV cirrhosis patients, they had poorer graft survival (60% vs. 70% at 5 years, respectively). When livers from diabetic donors were transplanted into diabetic recipients, they had much poorer graft survival than transplants from non-diabetic donors (54% vs. 77% at 5 years, respectively). 5. Split and partial liver transplants had poorer 5-year graft survival rates (58% and 57%, respectively) than whole liver transplants (62%), but the difference was mainly due to poorer outcomes during the first posttransplant year. 6. PELD allocation has resulted in improved one- and 3-year graft survival rates among pediatric liver recipients. Among adults MELD-based allocation has resulted in better one-year survival rates. When comparing the different original diseases, only HCC patients showed better one- and 3-year graft survival rates after MELD. 7. Within one year after transplantation, primary non-function and infection were the major causes of graft failure. These decreased after 1996, but recurrent hepatitis has increased as a cause of graft failure. After one year, chronic rejection and infection had decreased, while hepatitis recurrence still increased. 8. Cardiovascular deaths and deaths from multiorgan failure that occurred within the first year after transplantation have increased since 1996, while deaths due to infections have decreased. After the first year, deaths from graft failure increased, while CVD and infections decreased.

摘要

根据1987年至2005年向器官获取与移植网络/美国器官共享联合网络肝脏移植登记处报告的数据,我们发现:1. 尸体供肝移植的数量逐年缓慢增加,大部分增长发生在成年受者中。另一方面,活体供肝移植数量在2002年后急剧下降,此前在1998年至2001年的3年里,儿童和成年受者的活体供肝移植数量均迅速增加。2. 在过去18年中,非胆汁淤积性肝病的尸体供肝受者数量增长非常迅速。2002年实施终末期肝病模型(MELD)后,恶性疾病作为终末期肝病的病因有所增加。在活体供肝受者中,非胆汁淤积性疾病在1998年至2001年急剧增加,但从2002年起下降。2002年后,作为活体供肝移植病因的恶性疾病减少。3. 在儿童受者中,活体供肝移植的5年移植物存活率高于尸体供肝移植;相比之下,成年受者的活体供肝移植移植物存活率低于尸体供肝移植。4. 在过去18年中,边缘供体的使用有所增加,包括老年供体、丙型肝炎病毒(HCV)阳性供体、心脏死亡后供体和糖尿病供体。将HCV阳性肝脏移植到HCV阳性肝硬化受者中时,其移植物存活率与HCV阴性供体肝脏相似,而移植到非HCV肝硬化患者中时,移植物存活率较差(5年时分别为60%和70%)。当将糖尿病供体的肝脏移植到糖尿病受者中时,其移植物存活率远低于非糖尿病供体的移植(5年时分别为54%和77%)。5. 劈离式和部分肝脏移植的5年移植物存活率(分别为58%和57%)低于全肝移植(62%),但差异主要是由于移植后第一年的结果较差。6. 儿童终末期肝病评分(PELD)分配使儿童肝脏受者的1年和3年移植物存活率得到改善。在成年人中,基于MELD的分配使1年存活率更高。比较不同的原发病时,只有肝细胞癌(HCC)患者在MELD后1年和3年的移植物存活率更高。7. 在移植后1年内,原发性无功能和感染是移植物失败的主要原因。这些在1996年后减少,但复发性肝炎作为移植物失败的原因有所增加。1年后,慢性排斥反应和感染减少,而肝炎复发仍在增加。8. 自1996年以来,移植后第一年内发生的心血管死亡和多器官功能衰竭死亡有所增加,而感染导致的死亡有所减少。1年后,移植物失败导致的死亡增加,而心血管疾病和感染导致的死亡减少。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验